People · Operator
Named in public records as an officer, director or promoter · active 2009–2025 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Metamark Genetics, Inc. | — | Biotechnology | Series B | $33.9M | $361.5M | 2009 |
| Bectas Therapeutics, Inc. | — | Biotechnology | Series A | $5.5M | $66.0M | 2022 |
| Regenimo Biosciences, Inc. | — | Biotechnology | Seed | $2.0M | $4.6M | 2025 |
Lynda Chin at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Lynda Chin on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Raju Kucherlapati | 2 | 4 |
| Norman C. Selby | 1 | 4 |
| Sharon Shacham | 1 | 4 |
| Gregory C. Critchfield | 1 | 3 |
| Mansoor Raza Mirza | 1 | 3 |
| Jon A. Brilliant | 1 | 2 |
| MICHAEL C. KAUFFMAN | 1 | 2 |
| Kenneth E. Weg | 1 | 2 |
| Lynda E. Chin | 1 | 1 |
| Ronan O'Hagan | 1 | 1 |
| Raju E. Kucherlapati | 1 | 1 |
| David E. Cordo | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.